Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers

Ann Oncol. 2011 May;22(5):1133-1140. doi: 10.1093/annonc/mdq584. Epub 2010 Nov 23.


Background: This study was conducted in order to evaluate the significance of circulating free DNA (CFDNA), blood plasma p53 antibodies (p53-Ab) and mutations of KRAS gene in the prognosis of ovarian epithelial cancers.

Patients and methods: A total of 126 patients were included in this study. KRAS mutations and CFDNA were detected by means of the PCR-restriction fragment length polymorphism (PCR-RFLP) and enriched by the PCR-RFLP method. Enzyme-linked immunosorbent assay was used to analyze plasma p53-Ab.

Results: KRAS mutations were detected in 27 (21.4%) of examined tumors. The frequency of KRAS mutations was especially high in mucinous cancers (P < 0.001). CFDNA and p53-Ab were frequently detected in patients with serous cancers in high grade (P < 0.001). The overall survival rate was significantly lower for patients with serous tumors and CFDNA and p53-Ab-positive than negative tumors (P = 0.022 and P < 0.001, respectively). In mucinous ovarian cancer, a worse overall survival was correlated with the KRAS mutations (P = 0.03).

Conclusions: The results of the present study suggested that a presence of KRAS mutations in mucinous ovarian cancer and CFDNA and p53-Ab in serous tumors was correlated with the highest risk of cancer progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies / blood*
  • Base Sequence
  • Biomarkers, Tumor / blood*
  • Carcinoma, Ovarian Epithelial
  • DNA / blood*
  • Female
  • Genetic Association Studies
  • Humans
  • Kaplan-Meier Estimate
  • Middle Aged
  • Neoplasms, Glandular and Epithelial / blood
  • Neoplasms, Glandular and Epithelial / diagnosis
  • Neoplasms, Glandular and Epithelial / mortality
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / mortality
  • Point Mutation
  • Prognosis
  • Proto-Oncogene Proteins / genetics
  • Proto-Oncogene Proteins p21(ras)
  • Sequence Analysis, DNA
  • Tumor Suppressor Protein p53 / immunology*
  • Young Adult
  • ras Proteins / genetics


  • Antibodies
  • Biomarkers, Tumor
  • KRAS protein, human
  • Proto-Oncogene Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • DNA
  • Proto-Oncogene Proteins p21(ras)
  • ras Proteins